The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Donald L. Smith(Synta Pharmaceuticals (United States)), David A. Proia(Synta Pharmaceuticals (United States))
Cited by 37
Related Papers
Relevance of Plant Growth Promoting Microorganisms and Their Derived Compounds, in the Face of Climate Change
|Agronomy|2020|118
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
|Investigational New Drugs|2012|79
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
|Investigational New Drugs|2014|73
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
|International Journal of Oncology|2012|60
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
|Investigational New Drugs|2013|58